200,000+ products from a single source!
sales@angenechem.com
Home > Quinoline > 100107-43-5
100107-43-5 | Isoquinolinesulfonamide
CAS No: 100107-43-5 Catalog No: AG0000YS MDL No:
Product Description
Catalog Number:
AG0000YS
Chemical Name:
Isoquinolinesulfonamide
CAS Number:
100107-43-5
Molecular Formula:
C9H8N2O2S
Molecular Weight:
208.2370
IUPAC Name:
isoquinoline-1-sulfonamide
InChI:
InChI=1S/C9H8N2O2S/c10-14(12,13)9-8-4-2-1-3-7(8)5-6-11-9/h1-6H,(H2,10,12,13)
InChI Key:
GZZCYMXZJQCAJU-UHFFFAOYSA-N
SMILES:
NS(=O)(=O)c1nccc2c1cccc2
Properties
Complexity:
296
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
208.031g/mol
Formal Charge:
0
Heavy Atom Count:
14
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
208.235g/mol
Monoisotopic Mass:
208.031g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
81.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.1
Literature
| Title | Journal |
|---|---|
| Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation. | Bioorganic & medicinal chemistry 20120215 |
| DNA intercalator stimulates influenza transcription and virus replication. | Virology journal 20110101 |
| Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. | PloS one 20110101 |
| Novel ocular antihypertensive compounds in clinical trials. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). | PloS one 20110101 |
| Essential role of microfibrillar-associated protein 4 in human cutaneous homeostasis and in its photoprotection. | Scientific reports 20110101 |
| The effects of cholera toxin on cellular energy metabolism. | Toxins 20100401 |
| The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status. | BMC cancer 20090101 |
| Design, synthesis and antimalarial activity of benzene and isoquinoline sulfonamide derivatives. | Bioorganic & medicinal chemistry letters 20080115 |
| Evolution and potential function of fibrinogen-like domains across twelve Drosophila species. | BMC genomics 20080101 |
| Protein kinase inhibitors reduce GABA but not glutamate release in the nucleus accumbens. | Neuropharmacology 20071201 |
| A stochastic view of spliceosome assembly and recycling in the nucleus. | PLoS computational biology 20071001 |
| Photobleaching reveals complex effects of inhibitors on transcribing RNA polymerase II in living cells. | Experimental cell research 20070815 |
| The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers. | Molecular cancer 20060101 |
| Identification and characterization of the fibrinogen-like domain of fibrinogen-related proteins in the mosquito, Anopheles gambiae, and the fruitfly, Drosophila melanogaster, genomes. | BMC genomics 20050101 |
| Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis. | Biochemical and biophysical research communications 20020927 |
| Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. | Journal of neurochemistry 20020401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.